140 related articles for article (PubMed ID: 33955700)
1. Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model.
Krishnatry AS; Voelkner A; Dhar A; Prohn M; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):709-722. PubMed ID: 33955700
[TBL] [Abstract][Full Text] [Related]
2. Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors.
Krishnatry AS; Hanze E; Bergsma T; Dhar A; Prohn M; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):556-568. PubMed ID: 34648693
[TBL] [Abstract][Full Text] [Related]
3. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Cousin S; Blay JY; Garcia IB; de Bono JS; Le Tourneau C; Moreno V; Trigo J; Hann CL; Azad AA; Im SA; Cassier PA; French CA; Italiano A; Keedy VL; Plummer R; Sablin MP; Hemming ML; Ferron-Brady G; Wyce A; Khaled A; Datta A; Foley SW; McCabe MT; Wu Y; Horner T; Kremer BE; Dhar A; O'Dwyer PJ; Shapiro GI; Piha-Paul SA
Int J Cancer; 2022 Mar; 150(6):993-1006. PubMed ID: 34724226
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Piha-Paul SA; Hann CL; French CA; Cousin S; Braña I; Cassier PA; Moreno V; de Bono JS; Harward SD; Ferron-Brady G; Barbash O; Wyce A; Wu Y; Horner T; Annan M; Parr NJ; Prinjha RK; Carpenter CL; Hilton J; Hong DS; Haas NB; Markowski MC; Dhar A; O'Dwyer PJ; Shapiro GI
JNCI Cancer Spectr; 2020 Apr; 4(2):pkz093. PubMed ID: 32328561
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
8. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Lewin J; Soria JC; Stathis A; Delord JP; Peters S; Awada A; Aftimos PG; Bekradda M; Rezai K; Zeng Z; Hussain A; Perez S; Siu LL; Massard C
J Clin Oncol; 2018 Oct; 36(30):3007-3014. PubMed ID: 29733771
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.
Mizuno T; Fukuda T; Christians U; Perentesis JP; Fouladi M; Vinks AA
Br J Clin Pharmacol; 2017 May; 83(5):1097-1107. PubMed ID: 28000286
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.
Noh YH; Lim HS; Jung JA; Song TH; Bae KS
Cancer Chemother Pharmacol; 2015 Jan; 75(1):97-109. PubMed ID: 25377158
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors.
Wang E; DuBois SG; Wetmore C; Verschuur AC; Khosravan R
Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):343-352. PubMed ID: 33852135
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics-pharmacodynamics of sunitinib in pediatric patients with solid tumors.
Wang E; DuBois SG; Wetmore C; Khosravan R
Cancer Chemother Pharmacol; 2020 Aug; 86(2):181-192. PubMed ID: 32623479
[TBL] [Abstract][Full Text] [Related]
16. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies.
Falchook G; Rosen S; LoRusso P; Watts J; Gupta S; Coombs CC; Talpaz M; Kurzrock R; Mita M; Cassaday R; Harb W; Peguero J; Smith DC; Piha-Paul SA; Szmulewitz R; Noel MS; Yeleswaram S; Liu P; Switzky J; Zhou G; Zheng F; Mehta A
Clin Cancer Res; 2020 Mar; 26(6):1247-1257. PubMed ID: 31527168
[TBL] [Abstract][Full Text] [Related]
17. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Postel-Vinay S; Herbschleb K; Massard C; Woodcock V; Soria JC; Walter AO; Ewerton F; Poelman M; Benson N; Ocker M; Wilkinson G; Middleton M
Eur J Cancer; 2019 Mar; 109():103-110. PubMed ID: 30711772
[TBL] [Abstract][Full Text] [Related]
18. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types.
Lacy S; Yang B; Nielsen J; Miles D; Nguyen L; Hutmacher M
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1071-1082. PubMed ID: 29687244
[TBL] [Abstract][Full Text] [Related]
19. Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Odore E; Lokiec F; Cvitkovic E; Bekradda M; Herait P; Bourdel F; Kahatt C; Raffoux E; Stathis A; Thieblemont C; Quesnel B; Cunningham D; Riveiro ME; Rezaï K
Clin Pharmacokinet; 2016 Mar; 55(3):397-405. PubMed ID: 26341814
[TBL] [Abstract][Full Text] [Related]
20. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
